Clicky

HCW Biologics Inc.(HCWB)

Description: HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.


Keywords: Medicine Clinical Medicine Prostate Cancer Immunotherapies Acute Myeloid Leukemia Leukemia Pulmonary Fibrosis Treatment Of Acute Myeloid Leukemia Oncogenes Age Related Diseases Alopecia Areata Auto Immune Diseases Bisantrene Mustang Bio

Home Page: www.hcwbiologics.com

HCWB Technical Analysis

2929 North Commerce Parkway
Miramar, FL 33025
United States
Phone: 954 842 2024


Officers

Name Title
Dr. Hing C. Wong Ph.D. Founder, CEO, Director & Sec.
Ms. Rebecca Byam CPA, M.B.A. Chief Financial Officer
Dr. Peter Rhode Ph.D. Chief Scientific Officer & VP of Clinical Operations
Ms. Nicole Valdivieso Esq. VP of Legal Affairs
Ms. Raquel Diaz M.S. Director of HR
Mr. Lee D. Flowers Sr. VP of Bus. Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.728
Price-to-Sales TTM: 13.3337
IPO Date: 2021-07-20
Fiscal Year End: December
Full Time Employees: 44
Back to stocks